Question 1

What was Lincoln Pharmaceuticals' net profit in Q2 FY27?

Accepted Answer

Consolidated net profit was ₹20.4 crore, up 2.2% from ₹20 crore in Q2 FY26 and down 43.6% from ₹36.2 crore in Q1 FY27.

Question 2

What was Lincoln Pharmaceuticals' revenue in Q2 FY27?

Accepted Answer

Revenue from operations was ₹191 crore, up 17.1% year on year and up 7.9% from the previous quarter.

Question 3

What was Lincoln Pharmaceuticals' EPS in Q2 FY27?

Accepted Answer

Basic earnings per share were ₹10.20, against ₹9.98 in Q2 FY26.

Question 4

How were Lincoln Pharmaceuticals' Q2 FY27 results?

Accepted Answer

Both grew from a year earlier: net profit was up 2.2% at ₹20.4 crore and revenue was up 17.1% at ₹191 crore. The operating margin was 10.3%, down 3.0 percentage points from 13.4% a year earlier. Against Q1 FY27, net profit was down 43.6% and revenue up 7.9%.

Question 5

What was Lincoln Pharmaceuticals' operating margin in Q2 FY27?

Accepted Answer

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹19.8 crore, a margin of 10.3%, against 13.3% in Q1 FY27 and 13.4% in Q2 FY26. EBITDA was ₹23.7 crore, 12.4% of revenue.

Question 6

What was Lincoln Pharmaceuticals' net profit in the first half of FY27?

Accepted Answer

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹56.7 crore, up 18.9% from ₹47.7 crore in the same months a year earlier. Revenue from operations was ₹369 crore, up 16.1%.

Question 7

What is Lincoln Pharmaceuticals' net profit margin?

Accepted Answer

Lincoln Pharmaceuticals' net profit margin was 10.7% in Q2 FY27 (net profit as a share of revenue from operations), against 12.2% in Q2 FY26 (down 1.6 percentage points). For FY26 as a whole it was 13.1%.

Question 8

What was Lincoln Pharmaceuticals' net profit in FY26?

Accepted Answer

Consolidated net profit was ₹87.9 crore in FY26 (April 2025–March 2026), up 6.7% from ₹82.3 crore in FY25. It was ₹93.3 crore in FY24 and ₹72.9 crore in FY23: up 20.6% over three years, 6.4% a year on average.

Question 9

What was Lincoln Pharmaceuticals' revenue in FY26?

Accepted Answer

Revenue from operations was ₹671 crore in FY26 (April 2025–March 2026), up 7.7% from ₹623 crore in FY25. It was ₹581 crore in FY24 and ₹510 crore in FY23: up 31.5% over three years, 9.6% a year on average.

Question 10

How has Lincoln Pharmaceuticals' profit changed over the last four quarters?

Accepted Answer

Net profit by quarter: ₹28.6 crore in Q3 FY26, ₹11.6 crore in Q4 FY26, ₹36.2 crore in Q1 FY27 and ₹20.4 crore in Q2 FY27. That is ₹96.9 crore over the four quarters, up 21.1% from ₹80 crore in the four quarters before. Revenue from operations: ₹166 crore, ₹187 crore, ₹177 crore and ₹191 crore.

Question 11

When did Lincoln Pharmaceuticals announce its Q2 FY27 results?

Accepted Answer

On Thursday, 29 October 2026 at 12:30 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 13 November 2025.

Question 12

When will Lincoln Pharmaceuticals announce its Q3 FY27 results?

Accepted Answer

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Question 13

Where do these Lincoln Pharmaceuticals figures come from?

Accepted Answer

From Lincoln Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 29 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	191	163	+17.1%
EBITDA	23.7	25.4	−6.8%
EBITDA margin	12.4%	15.6%	−3.2 pts
Profit before tax	29.0	28.8	+0.7%
Net profit	20.4	20.0	+2.2%
EPS	₹10.20	₹9.98	+2.2%

Expenses
	191	177	187	166	163	154	168	147	161	147	142	146	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	9.5	24.3	−4.2	15.1	7.2	15.3	−6.9	9.0	10.0	10.4	7.0	11.0
	201	202	183	181	171	169	161	156	171	158	150	157
	77.5	58.6	73.7	47.7	57.2	61.0	53.9	50.2	57.1	52.7	51.9	56.9
	26.9	20.9	16.4	25.0	21.7	15.8	14.7	18.6	21.9	13.3	17.0	30.5
	−6.4	5.6	−1.1	3.3	−2.2	−7.4	11.5	−0.1	−6.7	4.2	4.7	−20.3
	31.3	33.3	32.5	30.6	30.4	31.8	27.6	28.0	27.8	29.0	25.1	26.4
	0.3	0.3	0.3	0.3	0.2	0.2	0.4	0.7	0.3	0.4	0.5	0.2
	3.9	3.9	3.7	3.7	3.6	3.5	3.2	3.2	3.2	3.2	2.7	2.8
	38.5	31.4	40.9	36.1	30.8	29.1	33.7	26.3	32.7	25.3	25.5	23.3
	172	154	166	147	142	134	145	127	136	128	127	120
	23.7	27.4	24.9	23.6	25.4	23.8	26.7	23.7	28.4	22.7	18.4	29.7
	19.8	23.5	21.2	19.9	21.8	20.3	23.5	20.4	25.2	19.5	15.7	26.8
Profit
	29.0	47.6	16.7	34.7	28.8	35.4	16.2	28.7	34.8	29.5	22.2	37.7
	29.0	47.6	16.7	34.7	28.8	35.4	16.2	28.7	34.8	29.5	22.2	37.7
	9.4	5.4	8.7	6.0	8.5	4.1	6.7	8.0	5.1	5.5	4.1	7.2
	−0.8	6.0	−3.6	0.1	0.3	3.6	−2.0	−0.1	3.3	0.3	−0.5	2.5
	8.6	11.3	5.1	6.1	8.8	7.7	4.7	7.9	8.5	5.8	3.6	9.7
	20.4	36.2	11.6	28.6	20.0	27.7	11.6	20.8	26.3	23.7	18.6	28.0
	20.4	36.2	11.6	28.6	20.0	27.7	11.6	20.8	26.3	23.7	18.6	28.0
	0.4	0.4	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	−0.1
	20.8	36.7	13.2	28.6	20.0	27.7	11.6	20.8	26.3	23.7	18.9	28.0
	—	—	11.6	28.6	20.0	27.7	11.6	20.8	26.3	23.7	18.6	28.0
Per share
	₹10.20	₹18.09	₹5.81	₹14.28	₹9.98	₹13.82	₹5.78	₹10.37	₹13.15	₹11.82	₹9.28	₹14.00
	₹10.20	₹18.09	₹5.81	₹14.28	₹9.98	₹13.82	₹5.78	₹10.37	₹13.15	₹11.82	₹9.28	₹14.00
Other comprehensive income — detail
	0.4	0.4	1.6	0.0	0.0	0.0	0.0	—	—	—	—	—
	−0.4	−0.4	−1.6	−0.0	−0.0	−0.0	−0.0	—	—	—	—	—
	—	—	—	—	—	—	—	—	—	−0.0	—	—
	—	36.2	—	28.6	20.0	27.7	11.6	20.8	26.3	23.7	18.6	28.0
Per share — as-filed variants
	₹10.20	₹18.09	₹5.81	₹14.28	₹9.98	₹13.82	₹5.78	₹10.37	₹13.15	₹11.82	₹9.28	₹14.00
	₹10.20	₹18.09	₹5.81	₹14.28	₹9.98	₹13.82	₹5.78	₹10.37	₹13.15	₹11.82	₹9.28	₹14.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	93.4	92.1	98.2	90.4	86.6	84.7	88.0	77.9	88.9	77.0	68.9	79.4
	48.8%	52.0%	52.4%	54.3%	53.0%	55.0%	52.3%	53.2%	55.2%	52.3%	48.4%	54.2%
Adjusted (ex-exceptional items) — derived
	29.0	47.6	16.7	34.7	28.8	35.4	16.2	28.7	34.8	29.5	22.2	37.7
	20.4	36.2	11.6	28.6	20.0	27.7	11.6	20.8	26.3	23.7	18.6	28.0
	₹10.20	₹18.09	₹5.81	₹14.28	₹9.98	₹13.82	₹5.78	₹10.37	₹13.15	₹11.82	₹9.28	₹14.00

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	146.4	142.5	147.3	161.2	146.6	168.2	154.1	163.4	166.3	187.3	177.3	191.3
Other Income	11.0	7.0	10.4	10.0	9.0	-6.9	15.3	7.2	15.1	-4.2	24.3	9.5
Total Income	157.5	149.5	157.7	171.2	155.5	161.3	169.3	170.6	181.5	183.1	201.5	200.9
Expenses
+ Cost of Materials Consumed	56.9	51.9	52.7	57.1	50.2	53.9	61.0	57.2	47.7	73.7	58.6	77.5
+ Purchases of Stock-in-Trade	30.5	17.0	13.3	21.9	18.6	14.7	15.8	21.7	25.0	16.4	20.9	26.9
+ Changes in Inventories	-20.3	4.7	4.2	-6.7	-0.1	11.5	-7.4	-2.2	3.3	-1.1	5.6	-6.4
+ Employee Benefit Expense	26.4	25.1	29.0	27.8	28.0	27.6	31.8	30.4	30.6	32.5	33.3	31.3
+ Finance Costs	0.2	0.5	0.4	0.3	0.7	0.4	0.2	0.2	0.3	0.3	0.3	0.3
+ Depreciation & Amortisation	2.8	2.7	3.2	3.2	3.2	3.2	3.5	3.6	3.7	3.7	3.9	3.9
+ Other Expenses	23.3	25.5	25.3	32.7	26.3	33.7	29.1	30.8	36.1	40.9	31.4	38.5
Total Expenses	119.8	127.3	128.2	136.4	126.8	145.1	133.9	141.8	146.7	166.4	154.0	171.9
EBITDA	29.7	18.4	22.7	28.4	23.7	26.7	23.8	25.4	23.6	24.9	27.4	23.7
EBIT	26.8	15.7	19.5	25.2	20.4	23.5	20.3	21.8	19.9	21.2	23.5	19.8
Profit
PBT before Exceptional Items	37.7	22.2	29.5	34.8	28.7	16.2	35.4	28.8	34.7	16.7	47.6	29.0
Pretax Income	37.7	22.2	29.5	34.8	28.7	16.2	35.4	28.8	34.7	16.7	47.6	29.0
+ Current Tax	7.2	4.1	5.5	5.1	8.0	6.7	4.1	8.5	6.0	8.7	5.4	9.4
+ Deferred Tax	2.5	-0.5	0.3	3.3	-0.1	-2.0	3.6	0.3	0.1	-3.6	6.0	-0.8
Tax Expense	9.7	3.6	5.8	8.5	7.9	4.7	7.7	8.8	6.1	5.1	11.3	8.6
Net Income	28.0	18.6	23.7	26.3	20.8	11.6	27.7	20.0	28.6	11.6	36.2	20.4
+ Net Income — Continuing Ops	28.0	18.6	23.7	26.3	20.8	11.6	27.7	20.0	28.6	11.6	36.2	20.4
+ Other Comprehensive Income	-0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.4	0.4
Total Comprehensive Income	28.0	18.9	23.7	26.3	20.8	11.6	27.7	20.0	28.6	13.2	36.7	20.8
Net Income to Common	28.0	18.6	23.7	26.3	20.8	11.6	27.7	20.0	28.6	11.6	—	—
Per Share
Basic EPS	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09	10.20
Diluted EPS	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09	10.20
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	0.0	0.0	0.0	0.0	1.6	0.4	0.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-0.0	-0.0	-0.0	-0.0	-1.6	-0.4	-0.4
+ Tax on Items NOT to be Reclassified — alt tag	—	—	-0.0	—	—	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	28.0	18.6	23.7	26.3	20.8	11.6	27.7	20.0	28.6	—	36.2	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09	10.20
Diluted EPS — Continuing Operations	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09	10.20
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	79.4	68.9	77.0	88.9	77.9	88.0	84.7	86.6	90.4	98.2	92.1	93.4
Gross Margin %	54.19	48.36	52.31	55.16	53.17	52.34	54.96	53.02	54.33	52.44	51.97	48.84
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	37.7	22.2	29.5	34.8	28.7	16.2	35.4	28.8	34.7	16.7	47.6	29.0
Net Income Adj (tax-effected)	28.0	18.6	23.7	26.3	20.8	11.6	27.7	20.0	28.6	11.6	36.2	20.4
EPS Adj	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09	10.20
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0

Lincoln Pharmaceuticals quarterly results

Every quarter

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Q2 FY27 results (July–September 2026)

Q2 FY27 at a glance · consolidated

Questions